semaj83/ctmatch_classification huggingface dataset:
Patient description: A 28-year-old female with neck and shoulder pain and left hand and arm paresthesias three weeks after returning from a trip to California where she attended a stray animal recovery campaign. Her physical exam was unremarkable except for slight tremors and almost imperceptible spasticity. She was prescribed NSAIDS and a topical muscle relaxant. She was brought in to the ER three days later with spastic arm movements, sweating, increasing agitation and anxiety, malaise, difficultly swallowing and marked hydrophobia, and was immediately hospitalized.

Clinical trial eligibility criteria: eligible ages (years): 2.0-6.0,  Cerebral Palsy Motor Deficits Clinical diagnosis of hemiparetic cerebral palsy consistent with in Swaiman and Russman (1999) and Badawi et al. (1998) Recommended for participation in pediatric rehabilitation and/or early intervention Lives within 50 miles of the Civitan Center at University of Alabama at Birmingham or the family is willing to temporarily relocate to the Birmingham area for treatment  Profound bilateral hearing loss with the use of hearing aids Severe visual impairment Serious seizure disorder or uncontrolled seizures Genetic and syndromic conditions historically excluded for CP registries Familial Spastic Paraplegia Ataxic Cerebral Palsy Diagnosis of Pervasive Developmental Disability or autism Serious or recurring medical complications Scheduled for surgery within 12 months of study entry
Patient description: A 28-year-old female with neck and shoulder pain and left hand and arm paresthesias three weeks after returning from a trip to California where she attended a stray animal recovery campaign. Her physical exam was unremarkable except for slight tremors and almost imperceptible spasticity. She was prescribed NSAIDS and a topical muscle relaxant. She was brought in to the ER three days later with spastic arm movements, sweating, increasing agitation and anxiety, malaise, difficultly swallowing and marked hydrophobia, and was immediately hospitalized.

Clinical trial eligibility criteria: eligible ages (years): 21.0-999.0,  Essential Tremor patients with a clinical diagnosis of essential tremor will participate in the study. Selection criterion is essential tremor with a history of ethanol responsiveness. Informed consent will be obtained by any of the co-investigators Patients must be off any medications used to treat essential tremor such as mysoline or propranolol for at least 2 weeks. Patients must withhold ethanol and caffeine 24 hours prior to starting the treatment periods through the end of treatment periods, including alcohol or caffeine containing over the counter medications. Ethanol and caffeine consumption is allowed in the washout period  Patients with abnormalities on neurologic exam other than tremor Patients with a history of chronic alcohol dependence Patients with chronic medical conditions such as renal failure, hepatic failure and chronic lung disease Patients on other medications that cannot be temporarily discontinued for the length of the study Patients, who, for moral or religious reasons, do not wish to take a potentially intoxicating drug Patients with abnormalities on their baseline screening laboratory tests Women who are pregnant or lactating Patients under the age of 21 Asians and Pacific Islanders
Patient description: A 28-year-old female with neck and shoulder pain and left hand and arm paresthesias three weeks after returning from a trip to California where she attended a stray animal recovery campaign. Her physical exam was unremarkable except for slight tremors and almost imperceptible spasticity. She was prescribed NSAIDS and a topical muscle relaxant. She was brought in to the ER three days later with spastic arm movements, sweating, increasing agitation and anxiety, malaise, difficultly swallowing and marked hydrophobia, and was immediately hospitalized.

Clinical trial eligibility criteria: eligible ages (years): 21.0-999.0,  Essential Tremor Patients with alcohol-responsive Essential Tremor Limb involvement should be a prominent feature of the Essential tremor Patients must be willing and able to safely stop and remain off any medications used to treat essential tremor for at least 4 half-lives Patients must be willing to abstain from ethanol and caffeine intake for at least 48 hours prior to starting the study hospitalization until study termination Patients must be willing and able to fast for periods of up to 12 hours during the study  Patients with abnormalities other than tremor on neurological exam Patients with active or past alcohol abuse or dependence Patients with acute or chronic severe medical conditions such as renal failure, hepatic failure or lung disease Patients taking primidone Patients on other acute or chronic medications that influence hepatic metabolism or central nervous system (CNS) function and cannot be temporarily discontinued for the length of the study Patients who do not wish to take a potentially intoxicating drug Patients with abnormalities on their baseline screening laboratory tests Women who are pregnant or lactating Patients younger than age 21 The presence of cognitive impairment preventing informed consent or cooperation during the study
Patient description: A 28-year-old female with neck and shoulder pain and left hand and arm paresthesias three weeks after returning from a trip to California where she attended a stray animal recovery campaign. Her physical exam was unremarkable except for slight tremors and almost imperceptible spasticity. She was prescribed NSAIDS and a topical muscle relaxant. She was brought in to the ER three days later with spastic arm movements, sweating, increasing agitation and anxiety, malaise, difficultly swallowing and marked hydrophobia, and was immediately hospitalized.

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Stroke Cerebrovascular Accident Subjects will be included in the study on the basis of the following They must be at least six months post-stroke years of age or older with a clinical diagnosis of hemiparesis (as verified by medical record and a medical expert) They have voluntary control with a low to medium range of motion function (UE-FT<5) and a muscle tone They are functionally stable (no significant changes in motor function over a week) and are able to tolerate being seated upright for 90 minutes They report no excessive pain the impaired arm If left neglect or spasticity is detected in the impaired arm, these levels must not interfere with the ability to cognitively complete the tasks or turn a wheel They must not be participating in any experimental rehabilitation or drug therapies If subjects are receiving chemical injections for spasticity, they must be at least 3-months away from their last treatment They must have driven prior to stroke  Subjects will be excluded from the study if they voluntarily decide to withdraw from the study or if they do not meet the above criteria Once informed consent is given twenty-four of these subjects will be randomized into two training groups (fun driving: fun and functional driving activities and rote tracking (12 subjects): rote and functional tracking activities). Two subjects will be randomized the case study group. The groups will be matched in initial motor function Subjects will be excluded if they voluntarily decide to withdraw from the study or if they do not meet the above criteria
Patient description: A 28-year-old female with neck and shoulder pain and left hand and arm paresthesias three weeks after returning from a trip to California where she attended a stray animal recovery campaign. Her physical exam was unremarkable except for slight tremors and almost imperceptible spasticity. She was prescribed NSAIDS and a topical muscle relaxant. She was brought in to the ER three days later with spastic arm movements, sweating, increasing agitation and anxiety, malaise, difficultly swallowing and marked hydrophobia, and was immediately hospitalized.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Post-stroke Upper Limb Spasticity Main Female or male patients ≥ 18 years ≥ 6 months since the last stroke, diagnosed by an appropriate health care professional (e.g., neurologist) Focal spasticity with ≥ 2 points on the Ashworth Scale in the wrist flexors with clinical pattern Flexed Wrist Focal spasticity with ≥ 2 points on the Ashworth Scale in the fingers flexors with clinical pattern Clenched Fist For pre-treated patients only: source documentation of the most recent injection session with Botulinum Toxin and sufficient therapeutic response for Flexed Wrist and Clenched Fist For pre-treated patients only: the most recent injection with Botulinum Toxin must have been maximal 50 Units BOTOX® or 200 Units Dysport® or 2000 Units Neurobloc® (type B preparation) per each of these flexors: carpi ulnaris, digitorum superficialis, digitorum profundus For pre-treated patients only: the most recent injection with Botulinum Toxin must have been maximal 60 Units BOTOX® or 240 Units Dysport® or 2400 Units Neurobloc® (type B preparation) for flexor carpi radialis Main  Spasticity of any other origin than stroke Previous treatment with Botulinum Toxin of any serotype and for any body region within the 4 months prior to Screening (Visit 1, Day -7) Planned concomitant treatment with Botulinum Toxin of any serotype and for any body region Previous or planned treatment with phenol or alcohol-injection in the target limb Previous surgical treatment of spasticity in the target muscle(s) Fixed contracture, defined as severe restriction of the range of joint movement on passive stretch Severe atrophy of the target limb muscles
Patient description: A 28-year-old female with neck and shoulder pain and left hand and arm paresthesias three weeks after returning from a trip to California where she attended a stray animal recovery campaign. Her physical exam was unremarkable except for slight tremors and almost imperceptible spasticity. She was prescribed NSAIDS and a topical muscle relaxant. She was brought in to the ER three days later with spastic arm movements, sweating, increasing agitation and anxiety, malaise, difficultly swallowing and marked hydrophobia, and was immediately hospitalized.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Upper Extremity Spasticity Stroke Acquired Brain Injury Minimum 6 months post injury/insult with unilateral upper limb spasticity of the elbow, wrist and/or finger flexors Preinjection Modified Ashworth scores > 2 in at least one of the following areas: elbow, wrist, or finger flexors Subjects must meet for CMA Hand Impairment Scale Stage 2 and be able to complete Task 3 (thumb to index finger) of the CMA Hand Impairment Scale Stage 3, or demonstrate 50% gross grasp to be included Botulinum toxin A (Botox®) stable patients (have received at least two prior doses of the agent with first dose occurring at least 6 months prior to study enrollment) Able to answer reliably to yes/no questions Able to follow reliably 1-step instructions Written informed consent Females enrolled in this study who are of childbearing age will be required to use adequate measures of birth control for the entire study period. Those who do not agree will be excluded  Uncontrolled, clinically significant medical condition other than the condition under evaluation Severe, fixed joint contracture in the affected arm. Patients with mild contracture that does not significantly impact function will be included based upon the assessment of the PI Known allergy or sensitivity to any of the components in the study medication Females who are pregnant, breast-feeding, or planning a pregnancy during the study or who think that they may be pregnant at the start of the study, or females of childbearing potential who are unable or unwilling to use a reliable form of contraception during the study Concurrent participation in another investigational drug or device study or participation in the 30 days immediately prior to study enrollment Treatment with botulinum toxin of any serotype for any reason in less than 3 months prior to initial date of injection for the study Any medical condition that may put the subject at increased risk with exposure to botulinum toxin type A including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other disorder that might interfere with neuromuscular function Evidence of recent alcohol or drug abuse Infection or skin disorder at an anticipated injection and/or electrical stimulation sites Any condition or situation that, in the investigator's opinion, may put the subject at significant risk, confound the study results, or interfere significantly with the subject's participation in the study
Patient description: A 28-year-old female with neck and shoulder pain and left hand and arm paresthesias three weeks after returning from a trip to California where she attended a stray animal recovery campaign. Her physical exam was unremarkable except for slight tremors and almost imperceptible spasticity. She was prescribed NSAIDS and a topical muscle relaxant. She was brought in to the ER three days later with spastic arm movements, sweating, increasing agitation and anxiety, malaise, difficultly swallowing and marked hydrophobia, and was immediately hospitalized.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Stroke Male or female, 18 to 70 years of age Written informed consent Written Authorization for Use and Release of Health and Research Study Information has been obtained Medically stable condition in the investigator's opinion History of stroke (hemorrhagic or ischemic) that resulted in a unilateral, upper-limb focal spasticity pattern of the wrist and fingers EMG evidence of volitionary activiation of wrist and finger extensor and flexor muscles Active range of motion (to be repeated 3 times by the patient): The ability to initiate wrist extension of at least 10 degrees from a fully flexed position with the forearm supported and stabilized in a pronated position. Active shoulder flexion and abduction to 45 degrees and no less than -30 degrees of elbow extension Mini-Mental State Exam (MMSE) >24 If on an anti-spasticity medication regiment at the time of qualification, the dose regimen must have been stable 1 month prior to study enrollment Ability to follow study instructions and likely to complete all required visits  Time since neurological event resulting in upper limb spasticity less than 3 months or greater than 24 months Previous therapy with BOTOX® or any other botulinum toxin serotype for any condition within the last 12 months Phenol or alcohol block in the study limb within 6 months of study enrollment visit History (within 3 months of qualification) of or planned (during study period) casting of the study limb Current treatment with an intrathecal baclofen pump In the opinion of the investigator, profound atrophy of the muscles in the study limb that are targeted for injection Previous surgical intervention in the study limb, except for routine orthopedic repair for bone fractures, in the last 6 months Presence of fixed contracture of the study limb impairing functional activity Clinically significant inflammation or condition in the study limb that, in the investigator's opinion, could limit joint movement (other than stroke or spasticity) Clinically significant spasticity or contracture of the elbow (defined as an Ashworth score >3) or shoulder in the study limb, in the investigator's opinion would limit sue of the wrist and fingers
Patient description: A 28-year-old female with neck and shoulder pain and left hand and arm paresthesias three weeks after returning from a trip to California where she attended a stray animal recovery campaign. Her physical exam was unremarkable except for slight tremors and almost imperceptible spasticity. She was prescribed NSAIDS and a topical muscle relaxant. She was brought in to the ER three days later with spastic arm movements, sweating, increasing agitation and anxiety, malaise, difficultly swallowing and marked hydrophobia, and was immediately hospitalized.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Alcohol Withdrawal Delirium Meet Diagnostic and Statistical Manual, 4th version, revised (DSMr-IV) for alcohol withdrawal syndrome (AWS) Be an inpatient at St. Mary's Medical Center (SMMC) or Miller Dwan Medical Center (MDMC) at time of study enrollment Have an alcohol withdrawal score as measured by standard SMMC or MDMC inpatient protocol sufficient to trigger the use of benzodiazepine withdrawal therapy Agree to abstain for alcohol for duration of study Be able to provide informed consent  The patient must not have any other active drug dependence in addition to alcohol Be unwilling or unable to forgo alcohol for the duration of the study Be using baclofen at the time of study enrollment Be using benzodiazepines for any reason other than acute alcohol withdrawal syndrome at time of study enrollment have known baclofen or benzodiazepine sensitivity Be unable to take oral (PO) meds Be unable to complete one of two consenting procedures Be pregnant or breastfeeding Have a serum creatine level > 2.0 Have a history of non alcoholic withdrawal seizures
Patient description: A 28-year-old female with neck and shoulder pain and left hand and arm paresthesias three weeks after returning from a trip to California where she attended a stray animal recovery campaign. Her physical exam was unremarkable except for slight tremors and almost imperceptible spasticity. She was prescribed NSAIDS and a topical muscle relaxant. She was brought in to the ER three days later with spastic arm movements, sweating, increasing agitation and anxiety, malaise, difficultly swallowing and marked hydrophobia, and was immediately hospitalized.

Clinical trial eligibility criteria: eligible ages (years): 19.0-65.0,  Rabies Subjects free of obvious health-problems or with stable condition Male or female subjects aged ≥19 to ≤65 years BMI between ≥18 and ≤30 kg/m2  Prior history of active or passive rabies immunization Clinically significant acute illness or infection within 2 weeks before first dosing based on the clinical judgment of the investigator History and/or family history of clinically significant immunodeficiency or auto-immune disease Any clinically significant history of known or suspected anaphylaxis or hypersensitivity reaction Chronic administration of immunosuppressants or other immune-modifying drugs within 6 months before the first dose of investigational medicinal product
Patient description: A 28-year-old female with neck and shoulder pain and left hand and arm paresthesias three weeks after returning from a trip to California where she attended a stray animal recovery campaign. Her physical exam was unremarkable except for slight tremors and almost imperceptible spasticity. She was prescribed NSAIDS and a topical muscle relaxant. She was brought in to the ER three days later with spastic arm movements, sweating, increasing agitation and anxiety, malaise, difficultly swallowing and marked hydrophobia, and was immediately hospitalized.

Clinical trial eligibility criteria: eligible ages (years): 1.0-1.5,  Rabies Male and female 12-18 months old toddlers will be included in the study if they are in good health at time of entry into the study as determined by medical history, physical examination and clinical judgment of the investigator are available for all the visits scheduled in the study have been granted a written informed consent signed by their parents  a history of rabies immunization a history of Japanese encephalitis immunization or disease a significant acute or chronic infectious disease at the time of enrollment fever > 38.0 degree C (axillary) or/and significant acute or chronic infection requiring systemic antibiotic or antiviral therapy within the past 7 days before enrollment being under treatment with parenteral, oral and/or inhaled corticosteroids, immunosuppressive drugs or other specific anti-inflammatory drugs or having taken chloroquine during the two months period before enrollment administration of any vaccine within the past 14 days before enrollment known immunodeficiency or an autoimmune disease known hypersensitivity to neomycin, tetracycline, amphotericin-B planned surgery during the study period being enrolled in any other investigational trial contemporaneously
Patient description: A 28-year-old female with neck and shoulder pain and left hand and arm paresthesias three weeks after returning from a trip to California where she attended a stray animal recovery campaign. Her physical exam was unremarkable except for slight tremors and almost imperceptible spasticity. She was prescribed NSAIDS and a topical muscle relaxant. She was brought in to the ER three days later with spastic arm movements, sweating, increasing agitation and anxiety, malaise, difficultly swallowing and marked hydrophobia, and was immediately hospitalized.

Clinical trial eligibility criteria: eligible ages (years): 1.0-3.0,  Malaria Malaria Infection Males or females aged greater than or equal to 1 to less than 4 years Known residents of the village of Bancoumana, Mali or its surrounding area Good general health as determined by means of the screening procedure Available for the duration of the trial (24 months from enrollment) Willingness to have child participate in the study as evidenced by parents/legal guardians signing or fingerprinting the informed consent document  Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, chronic infectious or renal disease by history, physical examination, and/or laboratory studies including urinalysis Behavioral, cognitive, or psychiatric disease that in the opinion of the investigator affects the ability of the volunteer or the parent/legal guardian to understand and cooperate with the study protocol Pre-existing known autoimmune diseases including but not limited to: systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, or autoimmune thrombocytopenia Laboratory evidence of possible autoimmune disease determined by anti-dsDNA titer that equals or exceeds 25 IU Laboratory evidence of liver disease (alanine aminotransferase [ALT] greater than the upper limit of normal of the testing laboratory) Laboratory evidence of renal disease (serum creatinine greater than the upper limit of normal of the testing laboratory, or more than trace protein or blood on urine dipstick testing confirmed by repeat testing) Laboratory evidence of hematologic disease (absolute leukocyte count less than 3000/mm(3) or greater than 14,500/mm(3), absolute lymphocyte count less than 1000/mm(3), platelet count less than 120,000/mm(3), or hemoglobin less than 8.5 g/dL) Other condition that, in the opinion of the investigator, would jeopardize the safety or rights of a volunteer participating in the trial or would render the subject unable to comply with the protocol Participation in another investigational vaccine or drug trial within 30 days of starting this study, or while this study is ongoing History of a severe allergic reaction or anaphylaxis
Patient description: A 28-year-old female with neck and shoulder pain and left hand and arm paresthesias three weeks after returning from a trip to California where she attended a stray animal recovery campaign. Her physical exam was unremarkable except for slight tremors and almost imperceptible spasticity. She was prescribed NSAIDS and a topical muscle relaxant. She was brought in to the ER three days later with spastic arm movements, sweating, increasing agitation and anxiety, malaise, difficultly swallowing and marked hydrophobia, and was immediately hospitalized.

Clinical trial eligibility criteria: eligible ages (years): 4.0-18.0,  Chronic Constipation Less than 2 per week defecation Fecal incontinence Retentive behavior Pain at defecation and Hard stools  Medication use (calcium, antacid, diuretic and hematinic) Organic causes (spina bifid, hypothyroidism, hirschusprung disease, developmental delay neuropsychomotor, kidney disease and metabolic diseases)